| 1801 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy |
Poland |
67 |
| 1802 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy |
Poland |
65 |
| 1803 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome + Myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
67 |
| 1804 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
40 |
| 1805 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
58 |
| 1806 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
60 |
| 1807 |
Apheresis |
Allogeneic
|
Myelofibrosis Post. Polycythemia Vera
|
Hematology
|
2024
|
Standard Therapy |
Poland |
66 |
| 1808 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
67 |
| 1809 |
Apheresis |
Allogeneic
|
Myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
65 |
| 1810 |
Apheresis |
Allogeneic
|
Myeloproliferative Neoplasms
|
Hematology
|
2024
|
Standard Therapy |
Poland |
74 |
| 1811 |
Apheresis |
Allogeneic
|
Myeloproliferative Neoplasms/Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy |
Poland |
68 |
| 1812 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
23 |
| 1813 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
50 |
| 1814 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Poland |
50 |
| 1815 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
67 |
| 1816 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Poland |
46 |
| 1817 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Poland |
65 |
| 1818 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
66 |
| 1819 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma – relapse
|
Hematology
|
2024
|
Standard Therapy |
Germany |
54 |
| 1820 |
Apheresis |
Autologous
|
Nonseminoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
38 |
| 1821 |
Apheresis |
Allogeneic
|
Osteomyelitis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
65 |
| 1822 |
Apheresis |
Allogeneic
|
Post-Et-Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
59 |
| 1823 |
Apheresis |
Allogeneic
|
Post-Pv-Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
64 |
| 1824 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
60 |
| 1825 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
52 |
| 1826 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
67 |
| 1827 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Poland |
70 |
| 1828 |
Apheresis |
Allogeneic
|
Relapsed B-Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
12 |
| 1829 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
15 |
| 1830 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
10 |
| 1831 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
60 |
| 1832 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia Progressed To Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy |
Poland |
21 |
| 1833 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
63 |
| 1834 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2024
|
Standard Therapy |
Germany |
64 |
| 1835 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
56 |
| 1836 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
56 |
| 1837 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
64 |
| 1838 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
56 |
| 1839 |
Apheresis |
Autologous
|
Follicular lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
58 |
| 1840 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
65 |
| 1841 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
47 |
| 1842 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
69 |
| 1843 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
38 |
| 1844 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
65 |
| 1845 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
70 |
| 1846 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
64 |
| 1847 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
53 |
| 1848 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
60 |
| 1849 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
59 |
| 1850 |
Apheresis |
Autologous
|
Mantle cell lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
45 |
| 1851 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
66 |
| 1852 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
33 |
| 1853 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
64 |
| 1854 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
Germany |
59 |
| 1855 |
Apheresis |
Allogeneic
|
Primary myelofibrosis
|
Hematology
|
2024
|
Standard Therapy |
Germany |
55 |
| 1856 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2024
|
Standard Therapy |
Germany |
63 |
| 1857 |
Apheresis |
Allogeneic
|
Blastic Plasmacytoid Dendritic
|
Hematology
|
2024
|
Standard Therapy |
USA |
57 |
| 1858 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
32 |
| 1859 |
Apheresis |
Allogeneic
|
Macrofocal multiple myeloma
|
Hematology
|
2024
|
Standard Therapy |
USA |
75 |
| 1860 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
United Kingdom |
62 |
| 1861 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
USA |
52 |
| 1862 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Germany |
48 |
| 1863 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
United Kingdom |
71 |
| 1864 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Romania |
35 |
| 1865 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Lithuania |
47 |
| 1866 |
Apheresis |
Allogeneic
|
Diffuse large B-cell lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Australia |
46 |
| 1867 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
USA |
65 |
| 1868 |
Apheresis |
Allogeneic
|
Chronic lymphatic leukemia
|
Hematology
|
2024
|
Standard Therapy |
Norway |
52 |
| 1869 |
Apheresis |
Allogeneic
|
Chronic myelogenous leukemia
|
Hematology
|
2024
|
Standard Therapy |
Poland |
60 |
| 1870 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Hungary |
32 |
| 1871 |
Apheresis |
Allogeneic
|
Malignant histiocytosis
|
Hematology
|
2024
|
Standard Therapy |
Bulgaria |
41 |
| 1872 |
Apheresis |
Allogeneic
|
Myelodysplastic syndrome
|
Hematology
|
2024
|
Standard Therapy |
USA |
78 |
| 1873 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Hungary |
20 |
| 1874 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Italy |
58 |
| 1875 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy |
Portugal |
67 |
| 1876 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Italy |
63 |
| 1877 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Lithuania |
19 |
| 1878 |
Apheresis |
Allogeneic
|
Hodgkin lymphoma
|
Hematology
|
2024
|
Standard Therapy |
Russia |
34 |
| 1879 |
Apheresis |
Allogeneic
|
chronic lymphocytic leukemia Richters Transformation
|
Hematology
|
2024
|
Standard Therapy |
United Kingdom |
68 |
| 1880 |
Apheresis |
Allogeneic
|
Myelodysplasia
|
Hematology
|
2024
|
Standard Therapy |
Sweden |
66 |
| 1881 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Italy |
52 |
| 1882 |
Apheresis |
Allogeneic
|
Myelodysplasia
|
Hematology
|
2024
|
Standard Therapy |
Lithuania |
70 |
| 1883 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Germany |
72 |
| 1884 |
Apheresis |
Allogeneic
|
plasma cell leukemia
|
Hematology
|
2024
|
Standard Therapy |
USA |
59 |
| 1885 |
Apheresis |
Allogeneic
|
Fibrolamellar Carcinoma
|
Hematology
|
2024
|
Standard Therapy |
Czechia |
41 |
| 1886 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Italy |
59 |
| 1887 |
Apheresis |
Allogeneic
|
post-ET Myelofibrose
|
Hematology
|
2024
|
Standard Therapy |
Austria |
61 |
| 1888 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
USA |
55 |
| 1889 |
Apheresis |
Allogeneic
|
Myeloma Multiplex
|
Hematology
|
2024
|
Standard Therapy |
Poland |
67 |
| 1890 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Spain |
45 |
| 1891 |
Apheresis |
Allogeneic
|
Myelofibrose
|
Hematology
|
2024
|
Standard Therapy |
Spain |
69 |
| 1892 |
Apheresis |
Allogeneic
|
Myelofibrose
|
Hematology
|
2024
|
Standard Therapy |
Poland |
60 |
| 1893 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy |
USA |
53 |
| 1894 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
France |
35 |
| 1895 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Italy |
69 |
| 1896 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Norway |
18 |
| 1897 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Germany |
51 |
| 1898 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy |
Poland |
62 |
| 1899 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy |
Hungary |
56 |
| 1900 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy |
USA |
19 |
Albánia
Bosznia Herzegovina
Bulgária
Horvátország
Ciprus
Montenegró
Cseh Köztársaság
Dánia
Észtország
Spanyolország
Koszovó
Litvánia
Lettország
Luxemburg
Macedónia
Németország
Lengyelország
Portugália
Románia
Szerbia
Szlovákia
Szlovénia
Svájc
Svédország
Törökország
Magyarország
Egyesült Királyság
Olaszország
UAE
Hong-Kong
Kuvait
Libanon
Dél-Afrika
